Gennao Bio Appoints Claudine Prowse, Ph.D., as Chief Financial Officer

HOPEWELL, N.J.--(BUSINESS WIRE)--Gennao Bio, a privately held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced the appointment of Claudine Prowse, Ph.D., as chief financial officer, effective August 11, 2021. Dr. Prowse is an accomplished leader in the healthcare industry with more than 20 years of experience at small, mid and large cap biotechnology companies and investment banks.

“I am pleased to welcome Claudine to Gennao’s executive leadership team,” said Stephen Squinto, Ph.D., chief executive officer and chair of the board of Gennao Bio. “Claudine’s extensive experience with capital raising, strategy and corporate development will have an immediate and positive impact on Gennao during our current growth phase and beyond.”

Most recently, Dr. Prowse served as senior vice president of strategy and corporate development for Rocket Pharmaceuticals, Inc., where she provided leadership and execution across financing transactions and other strategic initiatives contributing to the company’s successful growth from small to mid-cap stage. Prior to this role, she was vice president of strategy, corporate development and investor relations officer at Inotek Pharmaceuticals Corporation, where she was instrumental in driving the strategy and leading the merger transaction with Rocket Pharmaceuticals, Inc. Dr. Prowse served in similar strategy and investor relations roles at Biogen, Inc., Human Genome Sciences and Ionis Pharmaceuticals, Inc., as well as vice president at Leerink Swann. She holds a Ph.D. in Biomedical Sciences from the University of California, San Diego (UCSD) School of Medicine and a B.S. in Biomedical Engineering from the UCSD School of Engineering.

“I am excited to be working with the team at Gennao to advance the company’s GMAB technology, with an initial focus on oncology and rare monogenetic skeletal muscle diseases,” commented Dr. Prowse. “This non-viral, targeted approach has the potential to transform genetic medicine and generate long-term value for our shareholders.”

About Gennao Bio

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.